Sep 29,2023

Massive Bio Stepping Forward at HLTH 2023

Massive Bio is gearing up to make a significant appearance at HLTH 2023 in Las Vegas. The Company's co-founders, CEO Selin Kurnaz, PhD, and Chief Medical Officer Arturo Loaiza-Bonilla MD announced that they will be joining the HLTH 2023 between 8-11th of October in Las Vegas.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 27,2023

Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes

Aitia today announced a collaboration with the Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer. This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer. Utilizing PanCAN’s health data platform, SPARK, Aitia will integrate PanCAN de-identified human multi-omic data to create Gemini Digital Twins, that will serve a wide range of applications, including the discovery of novel targets and biomarkers, simulation of drug candidates, identification of ideal patient subpopulations for clinical trials, and the determination of optimal drug combinations.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 25,2023 TOP STORY

ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING

In conjunction with Institut Kanser Negara's (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening at government clinics and hospitals under the Projek Saringan Awal Paru-Paru (SAPU) programme. Projek SAPU aims to act as a catalyst to encourage the adoption of AI x-ray screening by other government healthcare facilities, fostering a broader embrace of early screening for lung abnormalities as well as advancing research efforts in lung care. This initiative is part of AstraZeneca's early AI-powered lung cancer screening under its flagship Lung Ambition Alliance programme, which was first rolled out in 2021 at the primary care level with private clinics. A year later, AstraZeneca further expanded its early AI lung cancer screening programme by partnering with three (3) private tertiary hospitals to facilitate patient referral from the clinics, for further diagnosis using a low-dose computed tomography (LDCT) scan.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 11,2021

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation, a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. Initially and currently available in the United States, patients can now receive genetic counseling through Invitae’s partnership with Genome Medical, get testing, and upload their results within the Outcomes4Me app. According to Outcomes4Me patient data, almost half of users (46 percent) who qualified for testing (based on NCCN Guidelines) did not receive testing or did not know if they had received testing. However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment. 

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#self-tests

View Analyst & Ambassador Comments
Go to original news
Nov 22,2022

Outcomes4Me Wins 2022 UCSF Health Hub Digital Health Award and Announces its Reach Surpasses 20% of Recently Diagnosed Breast Cancer Patients

Outcomes4Me Inc., the developer of a personalized and evidence-based cancer navigation platform, announced today that the 2022 UCSF Health Hub Digital Health Awards recognized it as a Rising Star winner in the Consumer Prevention category. The company earned the award for its ability to empower patients with personalized care guidance. The recognition is particularly meaningful as it coincides with the company announcing that it has now supported more than 100,000 breast cancer patients as they navigate their illness and care.

View Analyst & Ambassador Comments
Go to original news
May 16,2023

Outcomes4Me and the National Comprehensive Cancer Network (NCCN) Expand Collaboration to Help Lung Cancer Patients

Outcomes4Me Inc., the developer of a personalized and evidence-based cancer navigation platform, and the National Comprehensive Cancer Network® (NCCN®) announced today that Outcomes4Me has newly incorporated the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer into its free app. The collaboration between Outcomes4Me and the NCCN dates back to 2019, when Outcomes4Me first integrated the NCCN Guidelines® for Breast Cancer. In 2021, the two groups expanded their collaboration when Outcomes4Me added the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic into its app, which raised awareness for the importance of genetic cancer risk screening. This latest extension of the years-long collaboration represents the formal launch of Outcomes4Me’s multi-cancer care efforts; its app is now fully available to lung cancer patients across the world, meeting an important need.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 19,2023 TOP STORY

Outcomes4Me Announces Investments to Accelerate Life-Saving Treatments for Cancer Patients

 Outcomes4Me Inc., the developer of the direct-to-patient, personalized and evidence-based cancer navigation platform, announced today it has entered into two innovative collaborations and investment structures, which together combine artificial intelligence (AI) technology, treatment awareness and education, diagnostic testing access and mass media to help more patients with cancer. Through an equity investment and collaboration agreement with Labcorp, Outcomes4Me aims to improve patient outcomes by novel precision oncology treatment options through information about and access to specialty biomarker testing, including comprehensive genomic profiling, offered by Labcorp. Additionally, Outcomes4Me and Forecast Labs, a division of Comcast NBCUniversal, have entered into an earned equity investment arrangement to provide access to performance-based TV advertising to accelerate patient acquisition for Outcomes4Me. 

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Sep 20,2023

New Online Tool Available to Help Health Care Providers Identify a Hard to Diagnose Breast Cancer

A new diagnostic scoring system, developed by renowned breast cancer experts, is now available as an easy-to-use online tool through Susan G. Komen®, the world’s leading breast cancer organization. This tool is to help health care providers recognize and effectively diagnose a rare and aggressive breast cancer, inflammatory breast cancer. The new Inflammatory Breast Cancer (IBC) Scoring System online tool is available at https://www.komen.org/ibc. Before the development of the proposed IBC Scoring System, IBC lacked a formal, objective medical definition and diagnosis was often delayed, misdiagnosed or missed altogether. The new online tool is intended to provide the proposed IBC diagnostic criteria in a convenient tool to help more quickly and effectively recognize IBC in the clinic.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Sep 20,2023 TOP STORY

Merck KGAA announces a partnership with BenevolentAI

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus on finding new small-molecule therapies in oncology, neurology and immunology. BenevolentAI, based in London, said it is in line for a “low double-digit million dollar upfront payment” in its agreement – which also starts with three programmes – with discovery, development and commercial milestones taking the potential value of the alliance to a maximum of $594 million. Merck has already developed its own in-house AI-based drug discovery engine called Addison, aimed at improving the probability of identifying drug-like molecules against a target and reducing the need to synthesise and screen compounds for activity in the lab. Merck’s chief medical officer, Danny Bar-Zohar, said the alliances will give the company an “end-to-end” AI platform that will “fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs.”

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 20,2023 TOP STORY

Merck puts $674 million into deal with Exscientia

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus on finding new small-molecule therapies in oncology, neurology and immunology. Oxford-based Exscientia is getting an upfront payment of $20 million in a deal focused on three projects, with up to $113 million on offer during the discovery phase and a total deal value of $674 million if all of them meet their objectives. Merck has already developed its own in-house AI-based drug discovery engine called Addison, aimed at improving the probability of identifying drug-like molecules against a target and reducing the need to synthesise and screen compounds for activity in the lab. Exscientia’s CEO, Prof Andrew Hopkins, said the Merck partnership will try to address “some of the hardest drug design challenges in cancer and immunology” while leveraging the German group’s “outstanding scientific acumen” and expertise in oncology and neuroinflammation.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY